EC SME Instrument Phase 1 Grant

---

June 20, 2018

SunRegen has received funding from the European Union’s SME Instrument Phase 1 program under grant agreement No 827153.

The EU SME Grant provides critical funding to innovative startups like SunRegen. It enables them to accelerate research. Moreover, it helps bring breakthrough healthcare solutions to market.

SunRegen received this grant under the European Union’s SME Instrument Phase 1 program (Grant No 827153). This demonstrates the company’s potential to advance cutting-edge therapies.

With the support of the EU SME Grant, SunRegen can expand research capabilities. The team can conduct detailed preclinical studies. In addition, they can optimize the development of therapies for neurodegenerative disorders. The funding allows collaboration with leading scientists. It also provides access to state-of-the-art laboratory facilities. These collaborations strengthen SunRegen’s capacity to innovate and ensure research meets high scientific standards.

Furthermore, the EU SME Grant helps SunRegen explore novel therapeutic approaches. It also supports refining project strategies and preparing for future development phases, including clinical trials. Additionally, the program provides guidance on business planning, regulatory pathways, and commercialization strategies. These elements are essential to translate research into practical healthcare solutions.

Participation in the grant program increases SunRegen’s visibility in the European biotech ecosystem. As a result, it creates opportunities for partnerships with investors, research institutions, and other startups. Moreover, it highlights the company’s commitment to scientific innovation, patient-centric solutions, and sustainable growth.

By leveraging the EU SME Grant, SunRegen strengthens its mission to improve patient outcomes through innovative therapies. It contributes to European healthcare advancements. In addition, it demonstrates leadership in developing regenerative medicine solutions.